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The precise roles that the major proteolytic pathways play in the regulation of skeletal muscle mass
remain incompletely understood, in part due to technical limitations associated with current techniques
used to quantify muscle protein breakdown (MPB). We aimed to develop a method to assess MPB in cells,
based on loss of puromycin labelling of translated polypeptide chains. Following an initial 24 h incu-
bation period with puromycin (1 mM), loss of puromycin labelling from murine C2C12 myotubes was
assessed over 48 h, both in the presence or absence of protein synthesis inhibitor cycloheximide (CHX).
To validate the method, loss of puromycin labelling was determined from cells treated with selected
compounds known to inﬂuence MPB (e.g. serum starvation, Dexamethasone (Dex), tumour necrosis
factor alpha (TNF-a) and MG-132)). Reported established (static) markers of MPB were measured
following each treatment. Loss of puromycin labelling from cells pre-incubated with puromycin was
evident over a 48 h period, both with and without CHX. Treatment with Dex (14 ± 2% vs. Ctl; P < 0.01),
TNF-a (20 ± 4% vs. Ctl; P < 0.001) and serum starvation (14 ± 4% vs. Ctl; P < 0.01) caused a greater loss
of puromycin labelling than untreated controls, while the proteasome inhibitor MG-132 caused a rela-
tively lower loss of puromycin labelling (þ15 ± 8% vs. Ctl; P < 0.05). Thus, we have developed a novel
decorporation method for measuring global changes in MPB, validated in vitro using an established
muscle cell line. It is anticipated this non isotopic-tracer alternative to measuring MPB will facilitate
insight into the mechanisms that regulate muscle mass/MPB both in vitro, and perhaps, in vivo.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Several proteolytic pathways exist in skeletal muscle to regulate
protein breakdown and maintain protein homeostasis. The
ubiquitin-proteasome pathway (UPP) plays a major role in regu-
lating muscle protein breakdown (MPB), where proteins targeted
for degradation by the UPP are initially polyubiquitinated by co-
valent attachment of a chain of ubiquitin molecules, which are then
recognised by the 26S proteasome for degradation [1,2]. Caspases
and calcium-activated calpains also contribute to protein break-
down in muscle, where it has been proposed that they may cleave
myoﬁbrillar proteins in order to make them more accessible toculoskeletal Ageing Research,
Research Centre, School of
, UK.
.J. Wilkinson).
r Inc. This is an open access articldegradation by the UPP [3e6]. The autophagy-lysosome system
also represents a major mechanism for protein degradation,
responsible for breakdown of organelles as well as bulk cyto-
plasmic and long-lived proteins [1,7].
While activation of the above proteolytic pathways has been
reported in muscle during various catabolic conditions, including
sepsis, fasting, sarcopenia and cachexia [2,3,6,7], methodological
difﬁculties have limited (versus muscle protein synthesis (MPS))
understanding of the role that MPB plays in these conditions. That
being said a number of techniques exist. For instance, 3-
methylhistidine (3-MH) [8] is a post-translational methylation of
histidine resulting from actin and myosin degradation. Since 3-MH
cannot be further metabolized or reincorporated, it has been used
as a marker of myoﬁbrillar proteolysis, and thus MPB [8e10].
However, limitations exist with this method, since 3-MH can also
be produced by other tissue types as well as from dietary meat
protein metabolism, while low concentrations make the quantiﬁ-
cation of 3-MH challenging [11,12]. Measurement of the rate of
release of labelled amino acid(s) from tissue/cells is anothere under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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with a radiolabelled or stable isotope of an amino acid that is
neither made nor catabolized by muscle (e.g. tyrosine), and its
subsequent release from tissue/cells under conditions where rein-
corporation is inhibited, can be used to estimate MPB [13]; often
requiring specialist equipment. Moreover, issues can arise when
labelled amino acids released during proteolysis are recycled for
MPS, giving rise to an underestimation of MPB rates, and these
methods require specialized equipment for measurement.
A number of years ago, the surface sensing of translation
(SUnSET) technique [14,15] was developed to study cellular global
protein synthesis both in cultured cells in vitro and in vivo animal
models as an alternative to classical radiolabelling or stable isotope
methods. Rather than using tracers to measure incorporation of a
labelled amino acid into protein, this technique involves incubation
with puromycin, an antibiotic that is a structural analogue of
tyrosyl-tRNA, which can be incorporated into a translating poly-
peptide chain [14]. Since incorporation of puromycin into a nascent
peptide chains results in the termination of peptide elongation, the
rate at which puromycin-labelled polypeptides are formed (anti-
puromycin antibodies serve to detect puromycin-conjugated pep-
tides) acts as an effective measure of global rates of protein
synthesis.
Crucially, as previously alluded to, a key advantage of the SUn-
SET method is that it does not require expensive/specialized
equipment and techniques; instead only common laboratory
methodologies, i.e. Western blot or immunohistochemistry. A
method for assessing MPB using similar non-tracer techniques
would undoubtedly be advantageous for research into muscle
protein metabolism. In this study, we hypothesised that a pur-
omyocin decorporation approach could be used for measuring
global changes in MPB i.e. following incubation periods with pu-
romycin, a subsequent decrease in puromycin labelling in cells
would be indicative of a change in MPB. We developed this method
in vitro using murine C2C12 myotubes, and validated the approach
using selected compounds known to dynamically modulate MPB.
2. Materials and methods
2.1. C2C12 cell culture
Mouse C2C12myoblasts (ECACC, Salisbury, UK) were cultured in
Dulbecco's Modiﬁed Eagle Medium (DMEM; Thermo Fisher Scien-
tiﬁc) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% (v/
v) antibiotic-antimycotic solution and 4 mM L-glutamine (all from
Sigma-Aldrich, UK) and maintained at 37 C with 5% CO2. For
experimentation, myoblasts (between passage 6 and 8) were
seeded onto six-well dishes (Nunclon™ Delta; Thermo Fisher Sci-
entiﬁc) and at ~90% conﬂuency, differentiation was initiated by
changing the medium to DMEM supplemented with 2% (v/v) horse
serum, 1% (v/v) antibiotic-antimycotic solution and 4 mM L-gluta-
mine (Sigma-Aldrich, UK). The media was replaced every 48 h.
2.2. Puromycin MPB method
Experiments were performed on day 4e5 post induction of
differentiation. Initial experiments assessed the time course of
puromycin incorporation into cellular protein, and its disappear-
ance from cells upon removal from the culture media, both in the
presence and absence of cycloheximide (CHX; ﬁnal concentration
25 ng/ml). For puromycin incorporation, cells were incubated for
1e24 h with puromycin (ﬁnal concentration 1 mM), after which
cells were harvested in homogenisation buffer for Western blot
analysis (see below). To determine the rate of puromycin loss from
cells, myotubes were incubated for 24 h with puromycin, then cellswere washed twice with Hanks' Balanced Salt Solution (HBSS), and
replaced with media lacking puromycin (with or without CHX).
Cells were harvested at various times points up until 48 h post
removal of puromycin.
For validation of the method, cells were incubated with selected
treatments known to inﬂuence muscle protein breakdown. Myo-
tubes were incubated for 24 h with puromycin, after which cells
were washed with HBSS and fresh media (without puromycin, and
with or without CHX) replaced. At this point, cells were subjected
to the following treatments: serum starvation, dexamethasone
(Dex; 1 mM; Sigma-Aldrich, UK), tumour necrosis factor alpha (TNF-
a; 10 ng/ml; Sigma-Aldrich, UK) or MG-132 (20 mM; Sigma-Aldrich,
UK). Samples were harvested after 4 h or 24 h treatment. All cells
were harvested by removing the media, washing twice with ice-
cold PBS, and collecting in homogenisation buffer (50 mM Tris-
HCl, pH7.5, 1 mM EDTA, 1 mM EGTA, 10 mM b-glycerophosphate,
50 mM NaF and complete protease inhibitor cocktail tablet (Roche,
UK). n¼ 4e6 technical well replicates were used for each treatment
group.
2.3. Western blotting
Cell lysates were prepared by passing samples repeatedly
through gel-loading pipette tips. Samples were centrifuged
(13,000 g for 10 min, 4 C) and lysates (10 mg total protein) were
electrophoresed using Criterion XT 12% Bis-Tris gels (Bio-Rad, UK)
at 200 V for 1 h. Samples were transferred to PVDF membranes at
100 V for 45min, andmembraneswere blocked in 5% (w/v) milk for
1 h at room temperature. Membranes were incubated overnight at
4 C in the presence of the following primary antibodies: puro-
mycin (1:20,000; Millipore), ubiquitin (1:2000; Cell Signaling
Technology), MAFbx (1:500), MuRF1 (1:2000; ECM Biosciences),
Calpain 1 (1:2000; Abcam), ULK1 Ser555 (1:2000; Cell Signaling
Technology) and Raptor Ser792 (1:2000; Cell Signaling Technol-
ogy). The following day, membranes were washed for 3  5 min
with TBS-Tween then incubated in HRP-conjugated secondary
antibody (anti-mouse 1:10,000 for puromycin; anti-mouse 1:2000
for Calpain 1; anti-rabbit 1:2000 for ubiquitin, MAFbx and MuRF1)
for 1 h at room temperature. Membranes were again washed in
TBS-Tween and bands were detected using Chemiluminescent HRP
Substrate (Millipore EMD) on a Chemidoc XRS imaging system (Bio-
Rad, UK). Bands were normalized against total protein loading by
Coomassie staining the membrane.
2.4. Statistical analyses
All data are presented as means ± SEM and analyzed using
GraphPad Prismversion 6 (La Jolla, USA). Unpaired t tests were used
to compare differences between treatments and untreated controls.
For the time course data, two-way ANOVA with Tukey's multiple
comparison test was used to assess differences between time
points and CHX treatment. P < 0.05 was taken to be statistically
signiﬁcant.
3. Results
3.1. Time course of puromycin incorporation into, and
disappearance from, C2C12 cells
C2C12 cells were harvested at various time points after addition
of puromycin to determine incorporation over a 24 h period. In the
absence of CHX, puromycin incorporation increased signiﬁcantly
over 24 h (þ1425 ± 42%; P < 0.001 vs. 1 h at 24 h; Fig. 1A, C), with a
linear rate of incorporation during 2 h-6h (Fig. 1D). With CHX,
puromycin incorporation was signiﬁcantly lower than in cells
Fig. 1. Time course of puromycin incorporation into C2C12 myotubes. C2C12 myotubes were incubated for various times with puromycin, without (A) or with (B) the addition of
cycloheximide (CHX). A & B, representative blots for puromycin labelling over time. Coomassie stained membranes are shown below. C, Puromycin labelling in cells over time,
expressed as relative arbitrary units (RAU), normalized to Coomassie and relative to ‘1 h eCHX’. D, Rate of puromycin incorporation into cells, expressed as RAU per hour. Data are
expressed as mean ± SEM, n ¼ 4 well replicates for each time point. a; P < 0.05 vs. 1 h time point. B; P < 0.05 vs. eCHX.
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increase in labelling by 4 h (þ196 ± 39%; P < 0.001 vs. 1 h; Fig. 1B
and C) and by 24 h was a 466 ± 23% increase in puromycin incor-
poration (P < 0.001 vs. 1 h).
24 h was selected as the initial incubation period for assessing
MPB. Cells were treated for 24 hwith puromycin, washed, and fresh
media replaced to assess loss of puromycin labelling over time.
During the initial 4 h after puromycin removal, no loss of labelling
was observed (Fig. 2A, C), but from 6 h until 48 h there was a
gradual decrease in puromycin-labelled polypeptides within the
cells (74 ± 2%; at 48 h; P < 0.001 vs. 1 h; Fig. 2A, C). Inclusion of
CHX at the point of puromycin removal did not prevent the loss of
puromycin from cells, although there was a delayed decline in
labelling, with signiﬁcant decreases in puromycin labelling from
24 h onwards (66 ± 3%; at 48 h; P < 0.001 vs. 1 h; Fig. 2B and C).3.2. Effects of selected treatments on loss of puromycin labelling in
C2C12 cells
Selected treatments known to inﬂuence muscle protein break-
down (serum starvation, Dex, TNF-a and MG-132) were used to
validate the method. Puromycinwas removed from the media after
24 h incorporation, at which point each treatment was added.
Following 24 h serum starvation, Dex and TNF-a, there was a
greater loss of cellular puromycin than in untreated cells (14 ± 4%;
P < 0.01 vs. Ctl; 14 ± 2%; P < 0.01 vs. Ctl; 20 ± 4%; P < 0.001 vs.
Ctl, respectively, Fig. 3A, C). With MG-132 treatment, there was a
relatively lower loss of puromycin labelling compared to untreated
controls (þ15 ± 8%; P < 0.05 vs. Ctl; Fig. 3A, C). A similar pattern of
changes was observed with each treatment when CHX was
included at the onset of treatment (Fig. 3B and C).3.3. Markers of MPB following incubation with treatments known
to inﬂuence MPB
MAFbx protein expression was increased following 4 h Dex
(þ207 ± 34%; P < 0.001 vs. Ctl), TNF-a (þ154 ± 47%; P < 0.01 vs.
Ctl) and MG-132 (þ138 ± 44%; P < 0.01 vs. Ctl) treatment (Fig. 4A),
while serum starvation caused a reduction in MAFbx protein
(76 ± 5%; P < 0.001 vs. Ctl). After 24 h, MAFbx protein was no
different from controls for all treatments except for serum star-
vation, where it was decreased relative to control (97 ± 0%;
P < 0.001 vs. Ctl; Fig. 4A). Protein expression of MuRF1 was un-
affected by serum starvation (Fig. 4B) but was increased at 4 h and
24 h with Dex (þ74 ± 8%; P < 0.05 vs. Ctl at 4 h, þ38 ± 24%;
P < 0.01 vs. Ctl at 24 h), TNF-a (þ117 ± 9%; P < 0.01 vs. Ctl at
4 h, þ80 ± 55%; P < 0.05 vs. Ctl at 24 h) and MG-132 (þ98 ± 26%;
P < 0.01 vs. Ctl at 4 h, þ63 ± 23%; P < 0.01 vs. Ctl at 24 h). Total
ubiquitinated protein was unaffected by each treatment except for
with MG-132, where there was a signiﬁcant increase at both time
points (þ60 ± 10%; P < 0.01 vs. Ctl at 4 h, þ174 ± 25%; P < 0.001 vs.
Ctl at 24 h; Fig. 4C).
Calpain 1 protein was not signiﬁcantly altered at either time
point with any of the treatments (Fig. 4D). Phosphorylation of ULK1
(Ser555; Fig. 4E) was signiﬁcantly increased at 4 h by serum star-
vation (þ61± 11%; P< 0.05 vs. Ctl), Dex (þ57± 10%; P< 0.05 vs. Ctl),
TNF-a (þ147 ± 17%; P < 0.001 vs. Ctl) and MG-132 (þ148 ± 11%;
P < 0.001 vs. Ctl). At 24 h, ULK1 Ser555 was increased relative to
controls with MG-132 (þ57 ± 14%; P < 0.05 vs. Ctl). Raptor phos-
phorylation (Ser792; Fig. 4F) was increased following 4 h TNF-a
(þ260 ± 9%; P < 0.001 vs. Ctl) and MG-132 (þ155 ± 23%; P < 0.001
vs. Ctl) treatments, while after 24 h, Raptor phosphorylationwas no
different from control for all treatments (Fig. 4F).
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Although much insight has been acquired into the molecules
and mechanisms involved in maintaining protein homeostasis in
skeletal muscle during health and during catabolic conditions such
as sarcopenia, cachexia, and disuse, ubiquitous methodological
difﬁculties in measuring MPB have somewhat limited progress. The
SunSET technique [14], based on the measurement of the rate of
formation of puromycin labelled peptides, has been established as a
valid and accurate approach for assessing protein synthesis in
multiple tissue types [16]. In the present study, we aimed to
determine whether following an initial incubation, loss of puro-
mycin labelling from cells could be used to measure changes in
protein breakdown.We developed this method in vitro using C2C12
myotubes, with selected treatments known to inﬂuence MPB to
validate the method.
During initial testing of our hypothesis, we determined the
optimal initial incubation period for puromycin incorporation in
our chosenmodel. In doing so, we observed that during the ﬁrst 6 h
puromycin incorporation was linear, and by 24 h, incorporation
rates appeared to be declining i.e. potentially reaching a level of
saturation. For this reason, we chose an initial incubation period of
24 h. Subsequent loss of cellular puromycin-conjugated poly-
peptides was monitored over a 48 h time course. During the initial
4e6 h period after puromycin removal, no loss of labelling was
observed. This could feasibly be due to a lack of breakdown during
this period, potentially through the addition of fresh media to cells
inhibiting protein breakdown (i.e. ‘feed’), but may also have beendue to ‘saturation’ of the puromycin signal. It is also feasible that
during this period there was still some incorporation of remaining
intracellular puromycin. From 6 to 48 h however, there was a
continual decline in puromycin labelling.
From these ﬁndings, 24 h was selected for validating this
method, but we suggest that for future studies, the end user should
optimise conditions to suit cell type and individual experimental
conditions. We also assessed loss of puromycin labelling in
C2C12 cells in the presence of CHX (added at the point of puro-
mycin removal) to eliminate the possibility that the observed
changes were inﬂuenced by changes inMPS (i.e. reincorporation). It
should be noted that the dose of CHX that we used did not
completely inhibit MPS (Fig. 1); however higher doses caused cell
viability issues after 24 h (cells in suspension), which would clearly
compromise the true experimental readouts of MPB. Moreover, the
addition of CHX did not prevent the decline in puromycin labelling
across 48 h (although by 48 h there was a smaller decrease in
labelling compared to cells without CHX). Therefore, the addition of
CHX hadminimal inﬂuences on puromycin decorporation such that
puromycin decorporationwere primarily attributable to changes in
total MPB. A limitation also exists to using CHX in that it has been
shown to inhibit MPB, albeit to a lesser extent than its effects on
MPS [17]; therefore we suggest that use of CHX is neither required
nor indicated, for this method.
The validity of this method was determined using treatments
known to modulate MPB i.e. where a relative decrease in puro-
mycin would indicate activation of MPB, and vice-versa. Serum
starvation has been reported to activate MPB in muscle, primarily
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also been linked with activation of MPB in C2C12 cells [19,20]. Our
results showed that 24 h treatments of either serum starvation, Dex
or TNF-a each caused a greater loss in puromycin labelling than
untreated cells; similar changes were observed when CHX was
included, indicating the effects were solely due to changes in MPB.
We also tested the method with an inhibitor of protein breakdown,
i.e. the proteasome inhibitor MG-132, and observed that there was
a relatively lower loss of puromycin labelling with MG-132,
consistent with an inhibition of MPB. These ﬁndings provide
further substantiation that our method could accurately detect
biologically driven changes in MPB in response to known catabolic
factors.
Reported protein markers of MPB were measured to further
verify the effects of each treatment. Both Dex and TNF-a caused
upregulation of MAFbx and MuRF1 protein, consistent with previ-
ously reported effects of these compounds on activation of UPP-
mediated protein breakdown [21,22]. Unexpectedly, MG-132 also
resulted in upregulation of MAFbx andMuRF1, however the ﬁnding
that ubiquitinated protein levels were increased by MG-132
conﬁrmed that proteasome-mediated MPB was inhibited. The
observed decrease in MAFbx with serum starvation was also un-
expected, although activation of autophagy with serum starvation
may underlie the observed increases in MPB [18]. This was some-
what supported by the upregulation of ULK1 Ser555 phosphory-
lation at 4 h with serum starvation, which has previously been
linked with activation of autophagy [23,24] under conditions ofstress. The three other conditions evaluated (Dex, TNF-a and MG-
132) also showed increased ULK1 phosphorylation, with raptor
phosphorylation, which is important for autophagy regulation via
mTOR [25], also showing an increase with TNF-a and MG-132
treatment, indicating that these conditions may have also modu-
lated autophagy pathways. Thus, measurement of known markers
of MPB largely conﬁrmed that our treatments were effectively
inﬂuencing MPB. A clear advantage with the present method was
that the same sample can be used to measure additional Western
blot targets, including markers of MPB. Moreover, these ﬁndings on
“static MPB markers” highlight the issues surrounding the use of
MPB markers as a proxy for actual changes in MPB i.e. we observed
MAFbx upregulationwithMG-132, a treatment where proteasome-
mediated degradation was inhibited, thus caution should be taken
when using protein markers to assess MPB; similar to what has
been shownwith mRNA translation pathways poorly correlating to
MPS [26,27]. In addition, these results also emphasize the impor-
tance of measuring such static protein markers at multiple time
points, since MAFbx protein had returned to control levels by 24 h
with Dex, TNF-a and MG-132.
In summary, we present a novel proof-of-concept ‘puromycin
decorporation’ method for assessing MPB via immunoblotting,
validated using muscle cells in vitro e as an extension of the pur-
omyocin incorporation method. This technique has potential for
use in other cell types as well as in vivo studies, although new
studies may require further optimisation in terms of puromycin
doses and incubation periods. A major advantage of this method is
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H. Crossland et al. / Biochemical and Biophysical Research Communications 494 (2017) 608e614 613that validation is relatively easily achievable and it does not require
expensive or specialized techniques or equipment. We anticipate
that this technique will allow for further insight into the role of
MPB in skeletal muscle protein metabolism with health and con-
ditions of muscle atrophy.
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